SkylineDx Completes Direct U.S. Buildout for Merlin CP-GEP Test
Rotterdam – September 12, 2026 -- SkylineDx has completed its transition from third-party distribution to a fully integrated U.S. commercial organization for Merlin CP-GEP, scaling its dedicated sales, marketing and clinical staff from three representatives in early 2025 to more than 25 professionals across key U.S. territories.
SkylineDx ends third-party U.S. distribution deals for melanoma test
The Rotterdam- and San Diego-based diagnostics company has concluded all third-party commercialization and licensing collaborations that previously handled U.S. market access for Merlin CP-GEP. The newly built direct organization now supports healthcare professionals, institutions and patients nationwide, with most new hires working directly with clinicians in the field.